Noreximide

Noreximide

SCHEMBL2109030

O=C1NC(=O)[C@H]2[C@@H]1[C@@H]1C=C[C@H]2C1

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
TDP1 Q9NUW8 2/20 0.48
RAB9A P51151 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
HTT P42858 2/20 0.41
LMNA P02545 1/20 0.41
RECQL P46063 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
POLB P06746 1/20 0.39
PKM P14618 1/20 0.39
USP2 O75604 2/20 0.38
TSHR P16473 2/20 0.38
HSD17B10 Q99714 1/20 0.38
KDM4E B2RXH2 2/20 0.37
MAPK1 P28482 1/20 0.37
MAPT P10636 2/20 0.37
CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Noreximide SCHEMBL16664270 1.00 ALDH1A1 (0.48) ALDH1A1TDP1RAB9AMEN1KMT2A
Noreximide SCHEMBL572054 1.00 ALDH1A1 (0.48) ALDH1A1TDP1RAB9AMEN1KMT2A
Noreximide SCHEMBL1105956 1.00 ALDH1A1 (0.48) ALDH1A1TDP1RAB9AMEN1KMT2A
Noreximide SCHEMBL14536593 1.00 ALDH1A1 (0.48) ALDH1A1TDP1RAB9AMEN1KMT2A
Noreximide SCHEMBL339739 1.00 ALDH1A1 (0.48) ALDH1A1TDP1RAB9AMEN1KMT2A
Noreximide SCHEMBL24120970 1.00 ALDH1A1 (0.48) ALDH1A1TDP1RAB9AMEN1KMT2A
Noreximide SCHEMBL17369118 1.00 ALDH1A1 (0.48) ALDH1A1TDP1RAB9AMEN1KMT2A
Noreximide SCHEMBL9073180 1.00 ALDH1A1 (0.48) ALDH1A1TDP1RAB9AMEN1KMT2A
Noreximide SCHEMBL17875126 1.00 ALDH1A1 (0.48) ALDH1A1TDP1RAB9AMEN1KMT2A
SCHEMBL16275149 0.88 ALDH1A1 (0.39) ALDH1A1TDP1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
CN-102863437-A Preparation method of lurasidone JINAN BESTCOMM PHARMACEUTICAL R & D CO LTD 2013-01-09 CN claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
US-20240158412-A1 UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF FAXIAN THERAPEUTICS, LLC 2024-05-16 US disclosed
EP-4288442-A1 UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF Faxian Therapeutics, LLC (US) 2023-12-13 EP disclosed
US-20230068959-A1 BRANCHED MULTI-FUNCTIONAL MACROMONOMERS AND RELATED POLYMERS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-03-02 US disclosed
WO-2022170198-A1 UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF FAXIAN THERAPEUTICS, LLC (US) 2022-08-11 WO disclosed
US-11338038-B2 Branched multi-functional macromonomers and related polymers and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2022-05-24 US disclosed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 US disclosed
US-20040141922-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2004-07-22 US disclosed
US-6680047-B2 FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS AMERSHAM HEALTH AS (NO) 2004-01-20 US disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-20020102217-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158412-A1 UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF USP7, USP28, USP1 ALDH1A1 1048/4885TDP1 914/4885RAB9A 1605/4885
US-20040141922-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 ALDH1A1 4549/4885TDP1 1645/4885RAB9A 1754/4885
US-11338038-B2 Branched multi-functional macromonomers and related polymers and uses thereof MSN, CAD, NEDD8 ALDH1A1 469/4885TDP1 2521/4885RAB9A 3373/4885
US-20230068959-A1 BRANCHED MULTI-FUNCTIONAL MACROMONOMERS AND RELATED POLYMERS AND USES THEREOF MSN, CAD, NEDD8 ALDH1A1 469/4885TDP1 2521/4885RAB9A 3373/4885
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 ALDH1A1 4459/4885TDP1 1721/4885RAB9A 1715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.